CN110225750A - 细菌性阴道病的治疗和预防方法 - Google Patents

细菌性阴道病的治疗和预防方法 Download PDF

Info

Publication number
CN110225750A
CN110225750A CN201780070201.0A CN201780070201A CN110225750A CN 110225750 A CN110225750 A CN 110225750A CN 201780070201 A CN201780070201 A CN 201780070201A CN 110225750 A CN110225750 A CN 110225750A
Authority
CN
China
Prior art keywords
treatment
weeks
subject
vaginal
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780070201.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·R·弗兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evofem Inc
Original Assignee
Evofem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evofem Inc filed Critical Evofem Inc
Publication of CN110225750A publication Critical patent/CN110225750A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780070201.0A 2016-10-04 2017-10-03 细菌性阴道病的治疗和预防方法 Pending CN110225750A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404061P 2016-10-04 2016-10-04
US62/404,061 2016-10-04
PCT/US2017/054943 WO2018067568A1 (en) 2016-10-04 2017-10-03 Method of treatment and prevention of bacterial vaginosis

Publications (1)

Publication Number Publication Date
CN110225750A true CN110225750A (zh) 2019-09-10

Family

ID=61831547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780070201.0A Pending CN110225750A (zh) 2016-10-04 2017-10-03 细菌性阴道病的治疗和预防方法

Country Status (6)

Country Link
US (2) US11419835B2 (enExample)
EP (1) EP3522879A4 (enExample)
JP (4) JP2019529572A (enExample)
CN (1) CN110225750A (enExample)
AU (1) AU2017338748A1 (enExample)
WO (1) WO2018067568A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352907B2 (ja) 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法
US20230346724A1 (en) * 2018-10-09 2023-11-02 Crapaud Bio Inc. Methods of Making and Using pH Modulating Compositions in the Reproductive System
JP7706226B2 (ja) * 2020-06-26 2025-07-11 小林製薬株式会社 粘膜洗浄用組成物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105008A1 (en) * 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20130005787A1 (en) * 2011-06-28 2013-01-03 Medicis Pharmaceutical Corporation High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
WO2014041378A2 (en) * 2012-09-14 2014-03-20 Cipla Limited Topical pharmaceutical composition
WO2015070072A1 (en) * 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
WO2015095793A1 (en) * 2013-12-19 2015-06-25 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
US20160008276A1 (en) * 2012-06-13 2016-01-14 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
US20160136193A1 (en) * 2003-06-13 2016-05-19 Idh Holding Aps Treatment of symptoms associated with bacterial vaginosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
PT956858E (pt) * 1998-04-30 2002-04-29 Renata Maria Anna Caval Vesely Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
AU2001243431B2 (en) * 2000-03-07 2006-05-25 Rush University Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
JP2009102407A (ja) 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Ｇリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
JP2004537525A (ja) 2001-06-11 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド ＰＰＡＲδアゴニストの投与による炎症性疾患の治療法
US7291477B2 (en) * 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
JP4712380B2 (ja) 2002-07-26 2011-06-29 三笠製薬株式会社 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20100069323A1 (en) 2006-11-10 2010-03-18 Rohto Pharmaceutical Co., Ltd. Composition for application to skin or mucosa
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
AU2008256689A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
CA2721457A1 (en) 2008-04-16 2009-10-22 Cipla Limited Topical combinations comprising an antimycotic agent and an antiviral agent
WO2009155118A1 (en) 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
US20120070476A1 (en) * 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
EP2440560A1 (en) 2009-06-10 2012-04-18 Ultimorphix Technologies B.v. The succinate of tenofovir disoproxil
EP2704694A4 (en) 2011-05-02 2014-11-19 Aptalis Pharmatech Inc RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY
EP2827854A1 (en) * 2012-03-19 2015-01-28 Dr. August Wolff GmbH & Co. KG Arzneimittel Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
ITMI20130794A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle vaginosi batteriche.
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
US9801839B2 (en) 2014-02-28 2017-10-31 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic method
US20190209502A1 (en) 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105008A1 (en) * 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20160136193A1 (en) * 2003-06-13 2016-05-19 Idh Holding Aps Treatment of symptoms associated with bacterial vaginosis
US20130005787A1 (en) * 2011-06-28 2013-01-03 Medicis Pharmaceutical Corporation High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
US20160008276A1 (en) * 2012-06-13 2016-01-14 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
WO2014041378A2 (en) * 2012-09-14 2014-03-20 Cipla Limited Topical pharmaceutical composition
WO2015070072A1 (en) * 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
WO2015095793A1 (en) * 2013-12-19 2015-06-25 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARLA J. KELLER等: "Phase I Randomized Safety Study of Twice Daily Dosing of Acidform Vaginal Gel: Candidate Antimicrobial Contraceptive", 《PLOS ONE》 *

Also Published As

Publication number Publication date
EP3522879A4 (en) 2020-06-03
US20190224150A1 (en) 2019-07-25
US11419835B2 (en) 2022-08-23
US20230081059A1 (en) 2023-03-16
AU2017338748A1 (en) 2019-05-02
WO2018067568A1 (en) 2018-04-12
EP3522879A1 (en) 2019-08-14
JP2019529572A (ja) 2019-10-17
JP2024133639A (ja) 2024-10-02
JP2022169581A (ja) 2022-11-09
JP2024138259A (ja) 2024-10-08

Similar Documents

Publication Publication Date Title
McCORMACK et al. Acute pelvic inflammatory disease: characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride
US20230081059A1 (en) Method of treatment and prevention of bacterial vaginosis
De Vita et al. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study
Ling Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis
Van Damme et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women
Perera et al. A pilot randomised controlled trial evaluating postoperative packing of the perianal abscess
CN117241810A (zh) 阴道微生物群相关方法、组合物和装置
Schwartz et al. Fourteen-day safety and acceptability study of the universal placebo gel
Chappell et al. EVO100 prevents chlamydia and gonorrhea in women at high risk of infection
EP3863620A1 (en) Methods of making and using ph modulating compositions in the reproductive system
Hashem et al. Comparative efficacy of lidocaine–prilocaine cream and vaginal misoprostol in reducing pain during levonorgestrel intrauterine device insertion in women delivered only by cesarean delivery: A randomized controlled trial
Chetty et al. Randomized trial of multi-strain Lactobacillus crispatus vaginal live biotherapeutic products after antibiotic therapy for bacterial vaginosis: study protocol for VIBRANT (Vaginal lIve Biotherapeutic RANdomized Trial)
Zhou et al. Effects of intravaginal conjugated oestrogen on pessary continuation for pelvic organ prolapse: multicentre, randomised, double blind, placebo controlled trial
US6479045B2 (en) Vaginal pH buffering for preventing miscarriage and premature labor, by treating or preventing bacterial vaginosis
Mauck et al. Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study
Güney et al. Intrauterine lidocaine plus buccal misoprostol in the endometrial biopsy
JP2015526407A5 (enExample)
Arnau et al. Lidocaine–prilocaine cream as analgesia for hysterosalpingography: a randomized, double blinded, controlled study
Oppegaard et al. The use of oral misoprostol for pre‐abortion cervical priming: a randomised controlled trial of 400 versus 200 μg in first trimester pregnancies
Mittal et al. Cervical priming with misoprostol before manual vacuum aspiration versus electric vacuum aspiration for first‐trimester surgical abortion
HK40013915A (zh) 细菌性阴道病的治疗和预防方法
Williams Sexually transmitted infections
Kovacs et al. Microbiological profile of the cervix in 1,000 sexually active women
Yvon et al. Teprotumumab
Mauck et al. Lea's Shield®: colposcopic and microbiological testing during 8 weeks of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013915

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190910

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40013915

Country of ref document: HK